Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 24Paclitaxel 20Carboplatin 19Taxes 7temsirolimus 6Trastuzumab 6Topotecan 5Radiotherapy 5Cisplatin 5atezolizumab 4Specimen Handling 4Nivolumab 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Gemcitabine 4Docetaxel 4Biopsy 4Bevacizumab 4olaparib 3lenvatinib 3dostarlimab 3Sirolimus 3Pemetrexed 3Irinotecan 3Interleukin-12 Subunit p35 3Fulvestrant 3Cetuximab 3Albumin-Bound Paclitaxel 3spartalizumab 2gedatolisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Endometrial Neoplasms × TAS-116 × Clear all
NCT05655598 2024-09-19

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Brown University

Phase 1 Withdrawn
GenitourinaryGynecologicSarcoma

Urinary Bladder Neoplasms, Sarcoma, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡